FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS




FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS

WEST PALM BEACH, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces Chief Executive Officer Seamus Lagan has provided the following Year-End Review to shareholders:

FOXO Shareholders:

As we rapidly approach year-end, I wanted to reach out to our shareholders to review key milestones of 2025 and preview our go-forward operating and growth strategy. Much of the foundation of the “new” FOXO was created in mid-2024 when the Company acquired both Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. (including its principal subsidiary, Scott County Community Hospital, Inc.). More recently, we expanded our portfolio of healthcare-related businesses through the acquisition of Vector BioSource, Inc.

Myrtle Recovery Centers

Since opening its doors in August 2023, Myrtle’s first location in Oneida, Tennessee has positioned itself as a leading provider of residential and medically supervised withdrawal treatment services for substance use disorders in greater Tennessee. Key aspects of the business include:

• Has served patients from 63 of 95 counties in Tennessee since opening
• Current average daily census of 28 (93% occupancy) compared to average daily census of 7.4 for 2024 (25% occupancy)
• Patient treatment mix is approximately 85% residential treatment services and 15% medically supervised withdrawal services
• Projected patient admissions of 550 for 2025 compared to 195 patient admissions in 2024
• Received numerous local and statewide accolades and has received awards for its community outreach and care model
• Been awarded funding through the State of Tennessee Opioid Abatement Fund for treatment of uninsured patients in Scott County, Tennessee
• Working with software developers on a mobile application called “Evana” that seeks to connect Myrtle’s post-discharge patient population with Myrtle care professionals with the goal of monitoring and meeting patient after-care needs. Myrtle expects the application will provide improved patient care and satisfaction after discharge, aid in development of a strong alumni support system as well as increase the overall awareness of Myrtle capabilities in the communities it serves.

With its Oneida facility consistently at capacity and having excess referrals, Myrtle is actively considering other locations to replicate its operating model.

Rennova Community Health (including Scott County Community Hospital)

Scott County Community Hospital, known as Big South Fork Medical Center, is FOXO’s flagship acute care hospital (designated as a Critical Access Hospital) serving Scott County, Tennessee and surrounding communities. The facility offers inpatient (including swing bed) services and outpatient and emergency room services alongside a range of ancillary services such as lab, radiology, pharmacy and respiratory services. Hospital profile:

• Projected to see over 7,000 ER patients in 2025 in addition to over 3,500 outpatient visits and 300 inpatient stays
• Recently added swing bed (inpatient) and wound care (inpatient and outpatient) services
• In-network with all major payors (including Medicare Advantage plans and Tennessee Medicaid managed care plans)

Vector BioSource

We believe our most recent acquisition of Vector BioSource, Inc. (“Vector”) establishes FOXO as a growing player in the pharmaceutical services sector. Vector sources biospecimens (blood, urine) and sells such biospecimens to the biotechnology and pharmaceutical research sectors both in the US and abroad. We expect Vector to generate approximately $1 million of net revenues for 2025 and expect significant growth of the business as we invest capital to build infrastructure, expand markets and secure propriety sources of supply. Moreover, we see significant additional acquisition opportunities in this sector.

Corporate and Growth Outlook

From a corporate perspective, we had an active year where several legacy liabilities were settled for cash or more often with FOXO preferred stock. In addition, we both strengthened and streamlined our corporate management team. Our financials demonstrate:

• Reported net revenues of approximately $12 million for the nine months ended September 30, 2025 and expect to exceed $15 million in net revenues for the full year ended December 31, 2025
• Strengthened equity—equity increased from $5.3 million at December 31, 2024 to $20.2 million at September 30, 2025
• Reduced debt from $10.2 million at December 31, 2024, to $7.1 million at September 30, 2025
• Settled in full the $2.3 million legacy liability to Smithline
• Restructured approximately $3.5 million of legacy PIK note debt to preferred stock

We remain optimistic in our operating subsidiaries and are looking intently at augmenting organic growth with acquisitions. In connection with the Company’s acquisition strategy, the Company formed a wholly owned subsidiary, FOXO Acquisition Corporation (“FAC”), that intends to serve as vehicle to make acquisitions and created a new series of preferred stock designated as Series E Cumulative Redeemable Secured Preferred Stock (“Series E Preferred Stock”). The Series E Preferred Stock is not convertible to common stock, is secured by the equity of FAC, has a 2.5% per annum cash dividend and a 5% per annum common stock dividend. Our most recent acquisition, Vector BioSource, Inc., was acquired using the FAC subsidiary and a portion of the acquisition consideration was in the form of Series E Preferred Stock. We intend to list our Series E Preferred Stock with its own trading symbol; however, an eventual listing is not a certainty.

After losing the NYSE American listing of our common stock in the third quarter of 2025 because our minimum share price did not meet the continued listing requirements for NYSE American, we continue to consider options to uplist our common stock to NYSE American or another recognized stock exchange; however, there is no certainty of an eventual uplist. We hope this can be achieved in 2026.

Sincerely,

Seamus Lagan
Chief Executive Officer

About FOXO Technologies Inc. (“FOXO”)

FOXO owns and operates four key subsidiaries.

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee.

Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for medically supervised withdrawal treatment and residential treatment and outpatient services for MAT and OBOT programs.

Vector BioSource, Inc. is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries.

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.

For more information about FOXO, visit www.foxotechnologies.com.

Forward-Looking Statements

This press release contains forward-looking statements that include words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions, are forward-looking statements. These statements are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Sebastien Sainsbury
ssainsbury@foxotechnologies.com
(561) 485-0151

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference




Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.

Presentation Details
Date: Monday, January 12, 2026
Time: 3:45pm PST
Webcast Link

The webcast will be available under the Investors section on the Company’s website, www.catalystpharma.com, and a replay will be available for at least 30 days.

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

CONTACT: Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com

Media Contact
David Schull or Olipriya Das, Russo Partners
(858) 717-2310, (646) 942-5588
david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com

Big Nova Gives $3 Million to Advance NMDP’s Mission and Help More Patients Receive Blood Stem Cell Transplants




Big Nova Gives $3 Million to Advance NMDP’s Mission and Help More Patients Receive Blood Stem Cell Transplants

Family donations over a decade inspired by loved one’s life-saving transplant helped NMDP surpass $100 million campaign goal

MINNEAPOLIS and ORLANDO, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — NMDP^SM announced today that Big Nova has made a transformational $3 million philanthropic gift that will support thousands of patients receiving life-saving cell therapy from selfless blood stem cell donors. This generous gift propelled NMDP to surpass its ambitious $100 million comprehensive campaign goal, representing a historic achievement that will advance the organization’s mission.

Big Nova’s recent donation will expand access to patient and donor assistance programs, helping more patients overcome the financial barriers associated with transplant and ensuring more donors can say “yes” when called. The gift is expected to have far-reaching impact, supporting thousands of patients and donors navigating the process of receiving or donating blood stem cells to treat more than 75 different blood cancers like leukemia or blood disorders like sickle cell disease.

“Our family knows the hope NMDP brings because we’ve lived it. We felt our worlds turn upside down when a loved one was diagnosed with leukemia, and when an unrelated donor stepped forward to offer her a chance at a cure, we were so grateful and wanted to give back,” said Sarah Asma, Executive Director, Big Nova, NMDP Foundation board member and $100 million campaign committee chair. “We are honored to continue to help more patients receive a second chance at life and help more families feel the same relief we did.”

Financial challenges are the No. 1 barrier patients cite to getting a blood stem cell transplant. Each day, NMDP receives 15 grant requests from patients needing help with transplant-related expenses like housing, transportation and medications. In 2025, NMDP provided more than $7 million in financial assistance to 3,405 patients.

Donor support is equally essential to NMDP’s mission. To ensure there is never a cost to donate, NMDP covers all travel expenses to donation centers for the donor and a companion, potential lost wages during donation and reimbursements for childcare, pet care or other needs during the approximately 40 hours committed over several weeks.

“Big Nova’s belief in our mission and their dedication to saving lives through cell therapy will have a lasting impact on thousands of patients and their families,” said Amy Ronneberg, CEO, NMDP. “Their support illustrates a family turning their loved one’s lifesaving experience into a powerful purpose: paying their gratitude forward to inspire hope and ensure that other patients have the same chance at a cure.”

In 2012, a young member of the Moore family received a blood stem cell transplant facilitated by NMDP. Since then, the Moore family has hosted recruitment drives, volunteered, and funded research, patient financial assistance, and recruitment programs.

Asma personally took on the role of campaign chair for NMDP’s $100 million comprehensive campaign launched in 2020 and the goal was recently met and surpassed. The Big Nova and Moore family’s gifts helped the organization achieve this historic fundraising milestone, which is critical to enabling more patients to access cell therapy.

The Moore family formed the Big Nova Foundation in 2023 to spark hope and ignite change among the causes near and dear to the family and the Central Florida community, which the family has called home for six generations.

Big Nova’s commitment reflects a deep connection to NMDP’s lifesaving work and vision of a world where every patient can receive their lifesaving cell therapy. Join this movement of hope and give a gift to support patients battling leukemia, lymphoma and other blood cancers or blood disorders by visiting: https://go.nmdp.org/BigNovaGive

About NMDP^SM
At NMDP^SM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives.

CONTACT: Contact:
Erica Sevilla
NMDP
esevilla@nmdp.org

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12




Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.

A live webcast of the presentation will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available following the event.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Jenna Cohen
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13




MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026.

44^th Annual J.P. Morgan Healthcare Conference

Date: Tuesday, January 13, 2026
Format: Company presentation and 1×1 meetings
Time: 3:45 p.m. PT/ 6:45 p.m. ET
Location: San Francisco, California

The live webcast can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.

About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.

Media Contact:
Cassidy McClain
Inizio Evoke Comms
cassidy.mcclain@inizioevoke.com
(619) 694-6291

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device




NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device

• Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner
• Investment led by Checkmate Capital as part of strategic partnership with Armstrong Asia
• First commercial units to be delivered in March 2026

LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) —  NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating pediatric attention-deficit/hyperactivity disorder (ADHD). NeuroSigma’s manufacturing partner for the project is Singapore-based Armstrong Asia, a leading manufacturer for the medical, automotive and consumer electronics industries, with operations across Asia and partnerships around the globe. The investment was led by Checkmate Capital, a strategic advisory and investment group headquartered in Pasadena, California. The investment and manufacturing project are part of a collaboration between Armstrong and Checkmate, stemming from their July 2025 strategic memorandum of understanding (MOU) focused on the development and manufacturing of new technologies, particularly in the medical device industry.

“This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device,” said Colin Kealey, M.D., President and CEO of NeuroSigma. “As we move into 2026, we look forward to working with Armstrong Asia to deliver this innovative product to patients and families throughout the world.”

“We would like to thank NeuroSigma and Checkmate for selecting Armstrong as their manufacturing partner for the second-generation Monarch eTNS device,” added Phyllis Ong, CEO of Armstrong Asia. “Armstrong’s engineering team is highly inspired to co-design and manufacture advanced medical devices, and we look forward to producing the device at scale to serve the millions of patients suffering from ADHD.”

In November 2025, NeuroSigma announced successful completion of its pilot commercialization program for the first-generation Monarch eTNS device. During the pilot phase, the company dispensed over 1,000 Monarch devices and over 100,000 of the daily disposable patches. Based on strong market demand, NeuroSigma is preparing to launch the second-generation Monarch eTNS device in late Q1 2026.

“Completion of this investment marks a significant milestone for NeuroSigma, Armstrong, and Checkmate,” said Tom Paschall, CEO of Checkmate Capital and NeuroSigma Director. “Within the medical device industry, we see favorable conditions for the external neurostimulation sector and the central nervous system therapeutics market in general. The Monarch eTNS device is a groundbreaking neuro-electronic product that provides patients, families, and physicians with an alternative to stimulant medications and the negative side effects associated with them.”

Patients, families, and healthcare providers interested in the second-generation Monarch eTNS device and its upcoming launch can learn more at: http://www.monarch-etns.com.

About NeuroSigma
NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients’ lives. The company’s lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit www.neurosigma.com. For more information on the Monarch eTNS System, please visit www.monarch-etns.com.

About Armstrong Asia
Armstrong Asia is a precision engineering manufacturer established in Singapore since 1974, specializing in flexible material solutions for safer, better and greener innovations. With 16 factories and 2,600 employees across Malaysia, Thailand, Indonesia, Vietnam, Philippines and China, it strives to offer international customers with strategic footprint and trusted quality across Asia. Serving hundreds of global brand owners and OEMs, we understand the importance of consistently driving customer-centric innovation, optimizing supply chain and operational excellence, especially for the medical industry. Our technical partners around the globe are also invaluable to knowledge-sharing and speed of innovation. For more information, please visit www.armstrongasia.com.

Contact:
Colin Kealey, M.D., President of NeuroSigma at CKealey@neurosigma.com   

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris




NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) —  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices.

These changes will become effective after the market closes on Friday, December 19, 2025.

The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading listed companies in France. Inclusion in these indices is expected to broaden Nanobiotix’s visibility among institutional investors, strengthen the Company’s presence within European equity markets, and increase exposure to index-linked investment strategies.

“It is an honor to join the CAC Mid 60 and SBF 120 indices on Euronext Paris,” said Laurent Levy, Chief Executive Officer of Nanobiotix. “We believe this admission reflects the continued confidence of the financial markets in our long-term strategy and the disruptive potential of our nanotherapeutic solutions. As Nanobiotix advances toward key milestones and continues expanding the horizon of physics-based medicine, we remain focused on disciplined execution and creating sustainable value for patients, partners, and shareholders.”

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Contacts

Attachment

• 2025-12-15 — NBTX — Added to CAC Mid60 + SBF120 Indicies — FINAL

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI




Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI

December 15, 2025

• Acquisition of SpectraWAVE’s next-generation technologies including HyperVue^TM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1^TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1]
• SpectraWAVE’s technologies have the potential to significantly increase adoption of coronary intravascular imaging and physiological assessment, especially when combined with Philips’ industry-leading Azurion image-guided therapy platform, supporting better outcomes [2] for more cardiac patients
• Acquisition will expand Philips’ existing intravascular imaging and physiological assessment device portfolio, featuring Eagle Eye Platinum digital IVUS and OmniWire iFR technology, to create a comprehensive offering in intravascular imaging and physiology solutions

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging [3]. SpectraWAVE’s intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide [4]. SpectraWAVE, based in Bedford, Massachusetts, was founded in 2017 and currently employs more than 70 people.

“Our global leadership in image guided therapy is driven by deep clinical collaboration combined with our latest technology insights across hardware, software and AI, to innovate interventional procedures for better and more patient impact. Our world-class portfolio integrates interventional systems and devices into one platform, Azurion, serving patients worldwide.

“We are doubling down on image-guided therapy and expanding our portfolio in the coronary intervention segment with the addition of SpectraWAVE’s AI-powered innovations in high-definition intravascular imaging and angio-based physiological assessment, enabling us to deliver better care for more people,” said Roy Jakobs, CEO of Royal Philips.

Percutaneous coronary interventions are minimally invasive procedures that leverage intravascular imaging and physiological assessment to treat coronary artery disease. A significant and growing body of evidence shows that the use of intravascular imaging and physiological assessment technologies significantly improves patient outcomes for percutaneous coronary interventions [5]. With its industry-leading Azurion image-guided therapy platform, integrated with its expanding portfolio of advanced diagnostic and treatment devices, Philips is driving the adoption of advanced healthcare technology to treat a growing and increasingly complex patient population.

“Philips shares our deep conviction that the convergence of intravascular imaging, coronary physiology and AI can fundamentally improve how every patient with coronary disease is treated. This partnership allows us to integrate and scale HyperVue and X1-FFR into the world’s leading image-guided therapy ecosystem, expanding choice for clinicians and supporting more consistent, high-quality care for the millions of patients who depend on coronary intervention each year,” said Eman Namati, PhD, CEO of SpectraWAVE.

“With today’s announcement we continue to expand the role of minimally invasive image guided therapy procedures, which are associated with better patient outcomes and improved cost-effectiveness [6][7]. The acquisition of SpectraWAVE’s next-generation technologies for coronary intravascular imaging and physiological assessment mark a significant step in expanding our portfolio with breakthrough, AI-powered technologies that help clinicians decide, guide, treat and confirm treatment in one setting,” said Bert van Meurs, Chief Business Leader Image Guided Therapy at Philips.

Expanding clinician choice and integrating AI across its coronary portfolio
SpectraWAVE’s HyperVue Imaging System is an intravascular imaging platform that combines DeepOCT (next generation comprehensive optical coherence tomography) and NIRS (near-infrared spectroscopy) into the Enhanced Vascular Imaging (EVI) novel imaging segment to provide detailed structural and compositional images of the coronary arteries during percutaneous coronary interventions, with rapid setup, acquisition, and automated AI image analysis. Combined with Philips’ Eagle Eye Platinum digital IVUS and IntraSight technologies, HyperVue will expand clinicians’ intravascular imaging toolbox – IVUS, DeepOCT, NIRS, and wire and angio-derived physiology – all orchestrated through integrated systems to tailor guidance to each patient and lesion.

SpectraWAVE’s X1-FFR is an angiography-derived, AI-enabled physiology solution that calculates Fractional Flow Reserve (FFR) from a single coronary angiogram, providing a non-invasive ischemia assessment and turning routine X-ray images into coronary physiology data for simplified percutaneous coronary intervention workflows. X1-FFR complements Philips OmniWire iFR technology by extending physiologic guidance to wire-free scenarios and equipping clinicians with a versatile toolkit to broaden the adoption of coronary physiology in daily practice.

Philips offers one of the most comprehensive image-guided therapy portfolios in the industry, providing solutions for visual guidance during minimally invasive procedures and image-guided therapy devices designed to enhance procedural efficiency and improve patient outcomes. At the heart of this portfolio is Azurion, Philips’ next-generation platform that brings advanced interventional tools together in a single, intuitive environment supporting a wide range of procedures across interventional cardiology, interventional radiology, neuroradiology and vascular surgery. Introduced in 2017, Philips Azurion is used to treat more than 7.6 million patients each year in over 80 countries.

Financial terms of the agreement are not disclosed.

[1] The SpectraWAVE HyperVue Imaging System and the Starlight Imaging Catheter is a US Class 2 device cleared by FDA through K221257 and K230691. The SpectraWAVE X1-FFR Software is a US Class 2 device cleared by FDA through K251355.
[2] Compared with angiography-guided Percutaneous Coronary Interventions.
[3] AI-derived algorithms are deployed on the device to support vessel segmentation and contouring. Analytical (non-AI) models are used for generating FFR values.
[4] Stark, B., Johnson, C., & Roth, G. A. (2024). Global prevalence of coronary artery disease: An update from the Global Burden of Disease Study. Journal of the American College of Cardiology, 83(13 Suppl), 2320. https://doi.org/10.1016/S0735-1097(24)04310-9
[5] Mandurino-Mirizzi, A., Munafò, A. R., Rizzo, F., De Francesco, R., Raone, L., Germinal, F., Montalto, C., Mussardo, M., Moci, M., Vergallo, R., Rocco, V., Fischetti, D., Dionigi, F., Godino, C., Colonna, G., Oreglia, J., Burzotta, F., Crimi, G., & Porto, I. (2025). Comparison of different guidance strategies to percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. International Journal of Cardiology, 422, 132936. https://doi.org/10.1016/j.ijcard.2024.132936
[6] Stone, G. W., Christiansen, E. H., Ali, Z. A., Andreasen, L. N., Maehara, A., Ahmad, Y., Landmesser, U., & Holm, N. R. (2024). Intravascular imaging-guided coronary drug-eluting stent implantation: An updated network meta-analysis. The Lancet, 403(10429), 824–837. https://doi.org/10.1016/S0140-6736(23)02454-6
[7] Gaster, A. L., Slothuus Skjoldborg, U., Larsen, J., Korsholm, L., von Birgelen, C., Jensen, S., Thayssen, P., Pedersen, K. E., & Haghfelt, T. H. (2003). Continued improvement of clinical outcome and cost effectiveness following intravascular ultrasound guided PCI: Insights from a prospective, randomized study. Heart, 89(9), 1043–1049. https://doi.org/10.1136/heart.89.9.1043

For further information, please contact:

Michael Fuchs
Philips Global External Relations
Tel.: +31 614 869 261
E-mail: michael.fuchs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 205 977 055
E-Mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other important information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Attachments

• Clinician and patient with Azurion and IntraSight
• DeepOCT Enhanced Vascular Imaging
• Philips and SpectraWAVE logos

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis




Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

• PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo
• The safety profile of tolebrutinib was consistent with previous studies

Paris, December 15, 2025. Results from the PERSEUS phase 3 study (clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its primary endpoint in delaying time to 6-month composite confirmed disability progression (cCDP) in participants with primary progressive multiple sclerosis (PPMS), which represents 10% of the overall multiple sclerosis patient population. Based on these results, Sanofi will not pursue regulatory registration for PPMS.

“We are disappointed by today’s results; however, we do believe that these results will improve our understanding of the underlying disease biology of multiple sclerosis,” said Houman Ashrafian, Executive Vice President, Head of Research & Development at Sanofi. “We extend our deepest appreciation to the study participants, their families, and healthcare professionals who support our scientific and innovative vision. Our commitment to the multiple sclerosis community remains unchanged, as do our efforts to pursue novel advancements that address existing unmet needs and we remain confident in the value tolebrutinib can bring to those living with non-relapsing secondary progressive multiple sclerosis.”

Preliminary analysis showed the safety profile was consistent with previous tolebrutinib studies. As previously reported, drug-induced liver injury (DILI) is an identified risk of tolebrutinib. Strict adherence to liver monitoring requirements, and prompt management of liver enzyme elevations, are important to mitigate DILI risk. Full safety and efficacy results will be presented at a forthcoming medical meeting.

Tolebrutinib was provisionally approved in the United Arab Emirates in July 2025 for the treatment of non-relapsing secondary progressive multiple sclerosis and to slow disability accumulation independent of relapse activity in adults. It is currently under regulatory review in the EU and other jurisdictions worldwide. Tolebrutinib was previously granted breakthrough therapy designation by the FDA in December 2024.

Financial considerations
Sanofi will conduct an impairment test in accordance with IFRS (IAS 36) on the intangible asset value attached to tolebrutinib with a status to be provided with Q4 and FY 2025 results in January 2026. The outcome of this test will have no impact to the business net income / business EPS and there is no change to the financial guidance for 2025.

About multiple sclerosis

MS is a progressive neurologic disorder characterized by accumulation of disability with shifts
in the underlying biology and dominant drivers of disability over time impacting clinical
presentation and treatment response. ​

The clinical presentation of PPMS is characterized by a slow, insidious neurologic decline, often with a predominance of spinal cord involvement, and symptoms gradually worsen over time without periods of improvement.

Secondary progressive multiple sclerosis typically refers to people with a previous diagnosis of relapsing MS who have stopped experiencing relapses but continue to experience disability accumulation, in the absence of relapses.

Addressing disability accumulation remains a significant unmet need in MS, as treatment options are limited.​

About PERSEUS
PERSEUS (clinical study identifier: NCT04458051) is a global, double-blind, randomized phase 3 clinical study which evaluated the efficacy and safety of tolebrutinib compared to placebo in participants with PPMS. Participants were randomized (2:1) to receive either an oral daily dose of tolebrutinib or matching placebo for up to approximately 60 months. The inclusion criteria for the study included participants aged 18–55 years old, a diagnosis of PPMS as per the 2017 revised McDonald criteria, an EDSS score ≥2.0 and ≤6.5 at screening, positive cerebrospinal fluid findings (OCBs and/or elevated IgG index) and either no access, intolerance, or perceived lack of efficacy to ocrelizumab.

The primary endpoint was six-month composite confirmed disability progression (cCDP), defined as increase over at least six months of ≥1.0 point from the baseline expanded disability status scale (EDSS) score when the baseline score is ≤5.5, or ≥0.5 points when the baseline EDSS score is >5.5, or ≥20% from the baseline T25-FW, or ≥20% from the baseline 9-HPT. Secondary endpoints included six-month confirmed disability progression, three-month cCDP, number of new/enlarging T2 lesions as detected by MRI, time to confirmed disability improvement, change in brain volume loss, change in cognitive function, quality of life, pharmacokinetics, as well as the safety and tolerability of tolebrutinib.

About tolebrutinib
Tolebrutinib is an investigational, oral, brain-penetrant Bruton’s tyrosine kinase inhibitor specifically designed to target smoldering neuroinflammation, a key driver of disability progression in MS. This mechanism addresses the underlying pathology of progressive MS by targeting the inflammatory processes that contribute to neurodegeneration and disability accumulation.

Tolebrutinib represents Sanofi’s commitment to developing innovative treatments that address the underlying causes of neurological diseases and potentially transform the treatment landscape. Standing at the intersection of neurology and immunoscience, Sanofi is focused on improving the lives of those living with serious neuro-inflammatory and neuro-degenerative conditions including MS, chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease, Parkinson’s disease, and age-related macular degeneration. The neurology pipeline currently has several projects in phase 3 studies across various diseases.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com  
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com  
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com  
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward-looking statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.

Attachment

• Press_Release

Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer




Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer

Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11,  The Lancet – one of the world’s most renowned  academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderson Cancer Center, the world’s leading hospital for cancer care, is the first-ever randomized controlled trial (RCT) to provide the highest level of evidence demonstrating the benefits of proton therapy over conventional radiotherapy for this indication.

Oropharyngeal cancer is a type of head and neck cancer that develops in the throat region, a highly sensitive area containing fragile, critical structures, making precisely targeted local treatments particularly relevant. It is a growing global health concern, with more than 100,000¹ new cases diagnosed annually. Standard treatment, with the current state-of-the-art photon radiotherapy, intensity-modulated radiation therapy (IMRT) and chemotherapy, often results in major side effects, including significant weight loss, dependence on feeding tubes, dry mouth, and loss of taste.

The trial involved over 20 institutions and enrolled 440 patients, representing the first-ever level 1 randomized phase 3 trial comparing Intensity-Modulated Proton Therapy (IMPT) with advanced photon therapy (IMRT).

The MD Anderson study delivers Level 1 evidence with the following key findings:

• Significant improvement in overall survival: Five-year overall survival rate of 90.9% with IMPT versus 81.0% with IMRT
• 42% reduction in the hazard of death with IMPT
• Significantly reduced rates of severe toxicities (grade 3 and above) compared to IMRT. Toxicities include lymphopenia, neutropenia, xerostomia, dysphagia, and gastrotomy-tube dependence.

Level 1 evidence is the strongest evidence in medical research in this case coming from a large well-conducted multicenter Randomized Controlled Trial (RCT) -. It provides the most reliable basis for informed clinical decision-making 

These results establish proton therapy as a transforming, safe, and patient-focused solution, poised to redefine the global standard of care for oropharyngeal cancer.

“This is important level 1 evidence that proton therapy has both a survival benefit and quality-of-life improvement for these patients and should be the standard of care for advanced cases of oropharyngeal cancer,” commented Steven Frank, M.D., executive director of technology and innovation and deputy division head of strategic programs for Radiation Oncology.  He added: “these results demonstrate the advantages of proton therapy for head and neck cancer patients, and this study could lay the foundation for increased accessibility for patients who may benefit.”

Luk Herremans, Chief Market Officer of IBA Proton Therapy, commented: “This publication in The Lancet truly marks an important milestone for the field of proton radiotherapy. This trial started more than 10 years ago and has robust long term follow-up data demonstrating clear quality-of-life benefits for patients being treated with proton therapy as well as a reduced hazard of death of 42%. The publication is an important landmark to transform proton therapy into the new standard of care for those patients.”

IBA congratulates Dr. Steven Frank, principal investigator at MD Anderson Cancer Center Clinical Trial Consortium, and all participating institutions and experts for their invaluable contributions to this pivotal research.

IBA previously referred to this trial at prepublication stage at the Capital Markets Day and in its Third Quarter Trading Update press release.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

CONTACTS
IBA
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

¹ Source: https://gco.iarc.fr/en

Attachment

• 251215-Lancet-PT-MDA-Level1-evidence-EN